文献速递糖尿病

1型糖尿病的当前与未来治疗

Current and future therapies for type 1 diabetes.
PubMed 文献 · Diabetologia · 2021-02-17

本文综述1型糖尿病治疗进展:胰岛素仍是基石,但免疫抑制/调节仅部分成功阻止β细胞破坏,现转向β细胞保护策略(抗原疫苗、维拉帕米、GLP-1受体激动剂等),同时强调管理已确诊患者的心代谢并发症。

要点

  • 胰岛素仍为1型糖尿病成熟治疗基石,但儿童和青少年患者仍面临严重并发症。
  • 免疫抑制/调节预防β细胞破坏仅部分成功,焦点转向β细胞自身保护。
  • β细胞救援策略包括口服胰岛素或肽类抗原疫苗及维拉帕米、GLP-1受体激动剂等。

核心结论

  • 1型糖尿病治疗需兼顾β细胞保护与已确诊患者的心代谢并发症管理。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 免疫抑制和调节策略在预防β细胞免疫介导破坏方面仅部分成功。
  • β细胞功能障碍可能由细胞因子驱动的炎症和其他应激因素导致。

关键数值与推荐

  • 抗原疫苗包括口服胰岛素或肽类;维拉帕米和GLP-1受体激动剂显示对β细胞应激有益。
  • 干细胞替代疗法需以自身免疫预防方法为前提。

临床怎么用

  • 对已确诊1型糖尿病应管理主要心代谢并发症,同时探索β细胞保护策略。

局限性

  • 原文未报告综述的检索策略、纳入标准及证据等级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In type 1 diabetes, insulin remains the mature therapeutic cornerstone; yet, the increasing number of individuals developing type 1 diabetes (predominantly children and adolescents) still face severe complications. Fortunately, our understanding of type 1 diabetes is continuously being refined, allowing for refocused development of novel prevention and management strategies. Hitherto, attempts based on immune suppression and modulation have been only partly successful in preventing the key pathophysiological feature in type 1 diabetes: the immune-mediated derangement or destruction of beta cells in the pancreatic islets of Langerhans, leading to low or absent insulin secretion and chronic hyperglycaemia. Evidence now warrants a focus on the beta cell itself and how to avoid its dysfunction, which is putatively caused by cytokine-driven inflammation and other stress factors, leading to low insulin-secretory capacity, autoantigen presentation and immune-mediated destruction. Correspondingly, beta cell rescue strategies are being pursued, which include antigen vaccination using, for example, oral insulin or peptides, as well as agents with suggested benefits on beta cell stress, such as verapamil and glucagon-like peptide-1 receptor agonists. Whilst autoimmune-focused prevention approaches are central in type 1 diabetes and will be a requirement in the advent of stem cell-based replacement therapies, managing the primarily cardiometabolic complications of established type 1 diabetes is equally essential. In this review, we outline selected recent and suggested future attempts to address the evolving profile of the person with type 1 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. von Scholten BJ, Kreiner FF, Gough SCL, et al. Current and future therapies for type 1 diabetes. Diabetologia. 2021. PMID: 33595677. doi:10.1007/s00125-021-05398-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。